Early evidence suggests GLP-1s were linked to lower risks of developing substance use disorders — from alcohol to opioids — and to fewer overdoses and deaths in people with existing addictions.

Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more ...

In a clinical trial, a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder (OUD) during pregnancy led to higher rates of ...

International researchers find ‘very little evidence’ medical form of the drug can treat anxiety, anorexia and other disorders ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release ...

Diagnoses of opioid use disorder and opioid overdoses were rare in the 12 months following index visits (n = 2362; 0.3%). The Epic model showed low sensitivity to correctly identify people at risk ...

Weekly injections led to higher opioid abstinence rate, with good infant outcomes ...

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients adherent to SUBLOCADE had the lowest inpatient, emergency ...

Buprenorphine was associated with a 50% reduction in mortality and improved treatment retention for adolescents with opioid use disorder.

U.S. Centers for Disease Control and Prevention data included some good news for the Mountain State, as numbers from October ...

By Sriparna Roy March 16 (Reuters) - Cannabis-based medicines have shown little evidence of effectiveness for treating most ...